Oramed Pharmaceuticals Inc
ORMP
Company Profile
Business description
Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. The company has developed an oral dosage form intended to withstand the harsh environment of the gastrointestinal tract and effectively deliver active insulin or other proteins. Its product pipeline includes ORMD-0801 for Diabetes, ORMD-0801 for NASH, and ORMD 0901.
Contact
1185 Avenue of the Americas
Third Floor
New YorkNY10036
USAT: +1 844 967-2633
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
13
Stocks News & Analysis
stocks
Meta earnings: Early look at Muse adoption impresses investors
We see the company’s momentum in its core advertising business, as well as adoption of Muse, as early signals that the firm’s AI playbook is working.
stocks
Tesla earnings: Shares fall on slower deliveries growth outlook; Raising valuation
Our increased valuation comes from higher full self-driving adoption assumptions and a lower near- and medium-term capital expenditures forecast.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,876.10 | 41.00 | -0.46% |
| CAC 40 | 7,811.26 | 110.42 | -1.39% |
| DAX 40 | 25,371.75 | 273.29 | -1.07% |
| Dow JONES (US) | 52,867.98 | 11.89 | 0.02% |
| FTSE 100 | 10,725.03 | 27.85 | -0.26% |
| HKSE | 22,976.16 | 41.48 | 0.18% |
| NASDAQ | 26,008.86 | 694.00 | -2.60% |
| Nikkei 225 | 61,825.26 | 1,082.58 | -1.72% |
| NZX 50 Index | 13,703.51 | 43.33 | -0.32% |
| S&P 500 | 7,663.43 | 93.74 | -1.21% |
| S&P/ASX 200 | 8,767.20 | 26.00 | -0.30% |
| SSE Composite Index | 3,622.93 | 35.09 | -0.96% |